172 related articles for article (PubMed ID: 24670536)
1. A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression.
Zhang W; Liu S; Liu K; Wang Y; Ji B; Zhang X; Liu Y
J Int Med Res; 2014 Jun; 42(3):611-8. PubMed ID: 24670536
[TBL] [Abstract][Full Text] [Related]
2. ADAM10 is overexpressed in human hepatocellular carcinoma and contributes to the proliferation, invasion and migration of HepG2 cells.
Yuan S; Lei S; Wu S
Oncol Rep; 2013 Oct; 30(4):1715-22. PubMed ID: 23912592
[TBL] [Abstract][Full Text] [Related]
3. Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells.
Liu S; Zhang W; Liu K; Ji B; Wang G
Mol Med Rep; 2015 Jan; 11(1):597-602. PubMed ID: 25323956
[TBL] [Abstract][Full Text] [Related]
4. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
5. Impact of ADAM10 gene polymorphisms on hepatocellular carcinoma development and clinical characteristics.
Shiu JS; Hsieh MJ; Chiou HL; Wang HL; Yeh CB; Yang SF; Chou YE
Int J Med Sci; 2018; 15(12):1334-1340. PubMed ID: 30275760
[TBL] [Abstract][Full Text] [Related]
6. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
7. miR-365 targets ADAM10 and suppresses the cell growth and metastasis of hepatocellular carcinoma.
Liu Y; Zhang W; Liu S; Liu K; Ji B; Wang Y
Oncol Rep; 2017 Mar; 37(3):1857-1864. PubMed ID: 28184920
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
[TBL] [Abstract][Full Text] [Related]
9. Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10.
Xu Y; Lai Y; Cao L; Li Y; Chen G; Chen L; Weng H; Chen T; Wang L; Ye Y
RNA Biol; 2021 Oct; 18(10):1408-1423. PubMed ID: 33206588
[TBL] [Abstract][Full Text] [Related]
10. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma.
Ko SY; Lin SC; Wong YK; Liu CJ; Chang KW; Liu TY
Cancer Lett; 2007 Jan; 245(1-2):33-43. PubMed ID: 16309826
[TBL] [Abstract][Full Text] [Related]
11. Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Arai J; Goto K; Stephanou A; Tanoue Y; Ito S; Muroyama R; Matsubara Y; Nakagawa R; Morimoto S; Kaise Y; Lim LA; Yoshida H; Kato N
J Gastroenterol Hepatol; 2018 May; 33(5):1075-1081. PubMed ID: 29055152
[TBL] [Abstract][Full Text] [Related]
12. Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma.
Gaida MM; Haag N; Günther F; Tschaharganeh DF; Schirmacher P; Friess H; Giese NA; Schmidt J; Wente MN
Int J Mol Med; 2010 Aug; 26(2):281-8. PubMed ID: 20596609
[TBL] [Abstract][Full Text] [Related]
13. ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma.
Yang CL; Jiang FQ; Xu F; Jiang GX
Tumour Biol; 2012 Oct; 33(5):1535-41. PubMed ID: 22581584
[TBL] [Abstract][Full Text] [Related]
14. The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Doberstein K; Pfeilschifter J; Gutwein P
Carcinogenesis; 2011 Nov; 32(11):1713-23. PubMed ID: 21880579
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: implications for tumor progression and prognosis.
Tao K; Qian N; Tang Y; Ti Z; Song W; Cao D; Dou K
Jpn J Clin Oncol; 2010 Jul; 40(7):645-51. PubMed ID: 20388695
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of ADAM10 expression inhibits metastasis and invasiveness of human hepatocellular carcinoma HepG2 cells.
Yue Y; Shao Y; Luo Q; Shi L; Wang Z
Biomed Res Int; 2013; 2013():434561. PubMed ID: 23936798
[TBL] [Abstract][Full Text] [Related]
17. Expression profile of ADAM10 and ADAM17 in allergic rhinitis.
Chueh HW; Park SK; Hur DY; Bae WY
Int Forum Allergy Rhinol; 2015 Nov; 5(11):1036-41. PubMed ID: 26250527
[TBL] [Abstract][Full Text] [Related]
18. Melanoma antigen-1 mRNA combined with alpha-fetoprotein mRNA levels in peripheral blood of patients with hepatocellular carcinoma: a predictor of postoperative recurrence or metastasis?
Zhang Y; Song T; Meng L; Wu X; Ba Y; Li Q
ANZ J Surg; 2009; 79(1-2):62-9. PubMed ID: 19183381
[TBL] [Abstract][Full Text] [Related]
19. Decreased expression of long non-coding LOC285194 predicts tumour progression and poor prognosis of hepatocellular carcinoma after curative hepatectomy.
Qiu J; Pan G; Li M
Postgrad Med J; 2020 Feb; 96(1132):79-83. PubMed ID: 31494574
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma.
Honda H; Takamura M; Yamagiwa S; Genda T; Horigome R; Kimura N; Setsu T; Tominaga K; Kamimura H; Matsuda Y; Wakai T; Aoyagi Y; Terai S
Sci Rep; 2017 Nov; 7(1):15485. PubMed ID: 29138461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
